ArticleStem cell research & therapy2025
Low dose IFNγ remodels enhancer landscape to potentiate mesenchymal stromal cell activation.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundInterferon gamma (IFNγ) priming is a prominent approach to enhance the immune-regulatory capacity of mesenchymal stromal cells (MSCs). Despite its potential, the concentration of IFNγ vary between studies, and how MSCs response to different concentrations of IFNγ is unclear.
methodsMSCs were treated with various concentrations of IFNγ (0, 1, 5, 10, 50, and 100 ng/mL) for 48 h. Followed by RNA sequencing (RNA-seq) and Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) to profile gene expression and chromatin accessibility, respectively. Integrative analysis was conducted to elucidate the epigenetic regulation of MSCs response to different doses of IFNγ.
resultsWe found that low dose IFNγ (1 ng/mL) treatment was sufficient to induced significant changes in gene expression and chromatin accessibility. RNA-seq revealed that IFNγ activated genes involved in immune response and inactivated genes related to cell-cycle regulation. ATAC-seq showed that IFNγ reduced global enhancer accessibility of MSCs, possibly by downregulation of the SWI/SNF complex. Moreover, IFNγ selectively opened enhancer regions associated with immune response genes while closing regions linked to proliferation-related genes. Motif enrichment analysis identified binding sites for transcription factors such as IRF and AP-1 family members in open and closed regions, respectively, highlighting selective regulatory mechanisms.
conclusionsThis study demonstrates that low dose IFNγ is sufficient to modulate the transcriptional and epigenetic landscape of MSCs by selectively altering enhancer landscape. Our results provide insights into the regulatory mechanisms underlying IFNγ priming and offer a resource for the rational design of strategies to optimize MSC licensing for therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.